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Abstract
Background: While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q],
responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of
chromosomal abnormalities with new karyotyping tools may better predict response to LEN.
Design and methods: We have studied clinical, molecular and cytogenetic features of 42 patients with MDS,
myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes and secondary acute myeloid leukemia (sAML)
without del[5q] by metaphase cytogenetics (MC) who underwent therapy with LEN.
Results: Fluorescence in situ hybridization (FISH) or single nucleotide polymorphism array (SNP-A)-based
karyotyping marginally increased the diagnostic yield over MC, detecting 2/42 (4.8%) additional cases with del[5q],
one of whom were responded to LEN. Responses were more often observed in patients with a normal karyotype
by MC (60% vs abnormal MC; 17%, p = .08) and those with gain of chromosome 8 material by either of all 3
karyotyping methods (83% vs all other chromosomal abnormalities; 44% p = .11). However, 5 out of those 6
patients received combined LEN/AZA therapy and it may also suggest those with gain of chromosome 8 material
respond well to AZA. The addition of FISH or SNP-A did not improve the predictive value of normal cytogenetics
by MC. Mutational analysis of TET2, UTX, CBL, EZH2, ASXL1, TP53, RAS, IDH1/2, and DNMT-3A was performed on 21 of
41 patients, and revealed 13 mutations in 11 patients, but did not show any molecular markers of responsiveness
to LEN.
Conclusions: Normal karyotype and gain of chromosome 8 material was predictive of response to LEN in non-del
[5q] patients with myeloid malignancies.
Keywords: Lenalidomide, del[5q], Metaphase cytogenetics, Fluorescence in situ hybridization, Single nucleotide
polymorphism array
Background
Lenalidomide (LEN) is particularly effective in patients
with myelodysplastic syndromes (MDS) and the del[5q]
cytogenetic abnormality [1-3]. In MDS-003, the phase II
registration trial of 148 lower-risk MDS patients with
del[5q] with or without other karyotypic abnormalities,
67% achieved transfusion independence with a complete
and partial cytogenetic response rate of 45% and 28%,
respectively [2]. There was no significant association
between karyotypic complexity and the frequency of a
cytogenetic response. LEN also has activity in a propor-
tion of MDS without del[5q] [4] and [5]. Transfusion-
dependent MDS patients low- or Int-1 by the Interna-
tional Prognostic Scoring System (IPSS) without del[5q]
achieved a 43% overall rate of hematologic improvement
[4]. However, there were no significant differences in
the rate of transfusion independence according to age,
sex, FAB type, IPSS category, cytogenetic pattern, or
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patients with del[5q] with or without other karyotypic
abnormalities, 27% achieved complete remission (CR),
including 67% of patients with isolated del[5q], vs. 1/1
and 0/27 patients with one or more than one additional
chromosomal abnormalities, respectively (P < .001) [3].
Recently, high-dose LEN therapy resulted in a 14% CR/
partial response (PR) rate in AML patients with del[5q]
[6], and a 30% CR/complete remission without complete
recovery of all blood counts (CRi) rate in older AML
patients without del[5q] [5]. To date, the presence of del
[5q] with or without additional chromosomal abnormal-
ities detected by metaphase cytogenetics (MC) remains
the best prognostic factor for response to LEN. As
patients without del[5q] can also show responses to
LEN, identification of additional markers of response/
resistance is of utmost importance. Clinically, cytoge-
netic abnormalities including cryptic deletions of 5q,
along with certain other mutations, may constitute addi-
tional lesions predictive of response. For instance, the
presence of TP53 mutations has been shown to be asso-
ciated with poor prognosis in azacitidine-treated MDS
patients [7], and in LEN-treated MDS or AML patients
with del[5q] [8,9].
The diagnostic yield of MC can be enhanced by appli-
cation of fluorescence in situ hybridization (FISH) for
targeted detection of chromosomal lesions including del
[5q], as this technique is considered to be more sensitive
and allow for detection of smaller clones [10]. Similarly,
single nucleotide polymorphism array (SNP-A)-based
karyotyping, due to its superb resolution, may allow for
detection of previously cryptic unbalanced chromosomal
defects [10] and [11]. Both techniques can be performed
on interphase cells, and thereby do not require cell
division.
In addition to mostly unbalanced cytogenetic defects,
mutations of a number of genes, including TET2
[12,13], UTX [14], CBL [15], EZH2 [16-18], ASXL1
[19-21], TP53 [7,22,23], RAS [24,25], IDH1/2 [26], and
DNMT3A [27] have been implicated in the pathogenesis
of MDS and may also modulate clinical features includ-
ing responsiveness to LEN.
We examined a cohort of patients without del[5q]
treated with LEN and explored the relationship between
molecular features and clinical response to LEN.
Methods
Patients
Bone marrow (BM) and/or peripheral blood (PB) were
collected from 755 patients with myeloid malignancies
seen at Cleveland Clinic (CC) and H. Lee Moffitt Cancer
Center between 2002 and 2010. First, a cohort of 122
patients, who were examined with all 3 cytogenetic
methods (MC, FISH and SNP-A) on the same sample,
was collected. Next, data from 42 patients with MDS
( 3 1 ;R A ,5 ;R A R S ,1 3 ;R C M D ,1 ;R A E B - 1 ,4 ;R A E B - 2 ,7 ;
MDS-U, 1), myeloproliferative neoplasms (MPN) (PMF,
2), MDS/MPN overlap syndrome (7; CMML-1, 2;
CMML-2, 2; MDS/MPN-U, 3), or 2 secondary acute
myeloid leukemia (sAML) without del[5q], who received
LEN for at least 8 weeks, were collected retrospectively.
The schedule and dosage of lenalidomide was primarily
10 mg/day (5 mg/day in a few cases) for 1-21 days, with
a 28-day cycle. All bone marrow biopsies were reviewed
and diagnoses confirmed at Cleveland Clinic and H. Lee
Moffitt Cancer Center. Response to LEN was defined by
the modified International Working Group (IWG)
response criteria (2006) [28]. Informed consent for sam-
ple and clinical information collection was obtained
according to protocols approved by the Cleveland Clinic
or the H. Lee Moffitt Cancer Center IRBs.
Cytogenetic analysis
Cytogenetic analysis was performed on marrow aspirates
and/or peripheral blood, in cases where bone marrow
samples could not be obtained, according to standard
methods (Figure 1). 20 metaphase spreads were exam-
ined per patient, if available. Chromosome preparations
were G-banded using trypsin and Giemsa (GTG) and
karyotypes were described according to ISCN [29].
Fluorescence in situ hybridization
FISH analysis was performed on cell pellets from unsti-
mulated cytogenetic cultures. Thresholds for interpreta-
tion as a positive result were established for each probe
at 3 standard deviations above the mean of 20 normal
bone marrow samples. In 27 cases, FISH analysis was
performed at an outside reference laboratory (Mayo
Clinic) using the following dual color probe sets: 5p15.2
(normal range; 0-4%)/EGR1 (5q31) (0-6%), CEP7 (0-5%)/
7q31 (0-7%), CEP8 (0-2%)/MYC (8q24) (0-2%) and
20q12 (0-5%)/20qter (0-5%). In 95 cases, FISH was per-
formed at CC using three dual color probe sets (Abbott
Molecular, Abbott Park, IL). The first probe set consisted
of D5S23 and D5S721 (5p15.2) labeled in Spectrum
Green (0-6%) and EGR1 (5q31) labeled in Spectrum
Orange (0-6%). The second probe set consisted of the
chromosome 7 centromere labeled in Spectrum Green
(0-5%) and D7S486 (7q31) labeled in Spectrum Orange
(0-7%). The third probe set consisted of the chromosome
8 centromere labeled in Spectrum Green (0-8%) and
D20S108 (20q12) labeled in Spectrum Orange (0-4%).
DNA extraction
DNA was extracted from whole bone marrow using the
ArchivePure Kit (5Prime, Gaithersburg, MD) per manu-
facturer’s instructions. The concentration of the DNA
was obtained using a ND-1000 spectrophotometer
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line, T lymphocytes (CD3+) were isolated using Robo-
Sep according to manufacturer’s protocol (StemCell
Technologies, Vancouver, BC, Canada).
Mutational analysis
Mutation screening was performed for genes known to be
mutated in myeloid malignancies (TET2, UTX, CBL,
EZH2, ASXL1, TP53, RAS, IDH1/2, and DNMT3A) in the
cases for which DNA was available (N = 21). All of the
coding exons for TET2, UTX, EZH2 and TP53 were
screened as previously reported [13-17] and [23]. Direct
genomic sequencing of exons 8 and 9 of CBL, exon 12 of
ASXL-1, exons 1 and 2 of N-RAS and K-RAS,e x o n4o f
IDH-1 and IDH-2,a n de x o n2 3o fDNMT3A was per-
formed as previously described [15,21,26,27,30]. The refer-
ence sequence from UCSC Genome Browser was used to
identify the position of each amino acid change listed in
Table 1 (TET2, uc003hxk.2; EZH2, uc003wfb.1; ASXL-1,
uc002wxs.1; KRAS, uc001rgp.1; DNMT-3, uc002rgc.1). In
selected cases CD3+ cells were purified and used as con-
trols to confirm the somatic status of mutations.
SNP-A cytogenetics
Affymetrix Gene Chip Mapping 250 K Assay Kit or
G e n o m e - W i d eH u m a nS N PA s s a yK i t6 . 0( A f f y m e t r i x ,
Santa Clara, CA) was used for analysis of 52 and 70
samples with myeloid malignancies, respectively. Follow-
ing Nsp I digestion (New England Biolabs, Ipswich,
MA), fragmented DNA was ligated to adaptor using T4
ligase (New England Biolabs) followed by PCR amplifi-
cation. The PCR product was hybridized to the array,
processed with the Fluidic Station 450 and scanned
using the Gene Chip Scanner 3000 (Affymetrix).
Biostatistical evaluation of SNP-A data
GeneChip Mapping 250 K Array data, signal intensity
and SNP calls were determined using Gene Chip Geno-
typing Analysis Software Version 4.0 (GTYPE). Copy
number and LOH were investigated using Copy Number
Analyzer for Affymetrix GeneChip Mapping (CNAG v.
3.0). For Genome-Wide Human SNP Array 6.0, the gen-
otype calls for each individual were determined by the
Birdseed version 1 genotype-calling algorithm,
embedded in the software included with the Affymetrix
Genotyping Console 2.0 (Affymetrix).
For detection of lesions we used the following diag-
nostic algorithm: lesions identified by SNP-A were com-
pared with the Database of Genomic Variants (http://
projects.tcag.ca/variation/) and our own internal control
series to exclude known copy number variants (CNVs).
In our internal control cohort, the largest area of copy
Chromosome 5    Normal Chromosome 5q   Deletion A B
Smoothed
copy number
Raw
copy number
Allele calls
Figure 1 Detection of chromosome 5 abnormalities by different cytogenetic techniques. Examples of normal chromosome 5 (A) and
deleted chromosome 5 (B) are presented. The deleted lesion is denoted by a shorter chromosome in MC (top left panel, blue arrow), a single
red signal in FISH (top right panel) and segmental copy number loss in the SNP-A karyotype (bottom panel).
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was 52.5 Mb and the average size of CN-LOH was 7.2
Mb. In addition, we observed that areas of LOH in con-
trols were exclusively interstitial. Consequently, areas of
LOH < 24.8 Mb (mean size ± 2SD) were excluded from
analysis in the patient set. Deletions and gains of chro-
mosomal material seen on metaphase karyograms and
SNP-A samples that showed a concordantly normal kar-
yotype by both MC and SNP-A testing were not further
confirmed. When possible, all other remaining new
defects were confirmed using paired analysis of CD3+
cells.
Statistical analysis
Demographic and baseline MDS disease characteristics
of all patients were summarized descriptively, using
medians and ranges. The response differences between 2
groups were compared using Fisher’s exact test, with a
two-sided alpha value of .05 denoting significance.
Results
Comparison between metaphase cytogenetics and other
cytogenetic methods
We first identified a cohort of 122 patients for whom
MC, FISH and SNP-A analyses were performed on the
same sample, to evaluate the additional yield of more
sensitive techniques for identifying del[5q]. In patients
with MDS (N = 82), MDS/MPN (N = 13), AML (N =
23), and MPN (N = 4), the detection rate of del[5q]
increased only marginally with the use of additional
techniques, from 24% (MC + FISH), to 25% (MC +
SNP-A), 25% (FISH + SNP-A) and 26% (all 3 methods)
(Figure 1, Table 2). We also identified 3 cases with copy
neutral loss of heterozygosity (CN-LOH) of 5q in this
cohort using SNP-A. One region of CN-LOH was found
in sAML with complex chromosomal abnormalities
including del[5][q13q33] by MC, and the other 2 CN-
LOH regions were detected in MDS cases with chromo-
somal abnormalities other than del[5q].
Clinical characteristics of non-del[5q] patients who had
LEN therapy
Clinical characteristics of the patients with myeloid
malignancies without del[5q] by MC and who received
LEN are summarized in Table 3; 31 patients received
LEN monotherapy (complete response [CR], N = 3;
Table 1 Mutation analysis in the cohort of LEN patients
Case Response TET2 UTX CBL EZH2 ASXL1 TP53 N-RAS K-RAS IDH1 IDH2 DNMT3A
1C R W T W T W T W T W T W T W T W T W T W T W T
2 CR WT WT WT WT L775fsX1 WT WT WT WT WT WT
3P R W T W T W T W T W T W T W T W T W T W T W T
4N R W T W T W T W T W T W T W T W T W T W T W T
5 CR WT WT WT WT E1102D WT WT WT WT WT R882H
6 PR P1681fsX2 WT WT WT P1277fsX2 WT WT WT WT WT WT
7C R W T W T W T W T W T W T W T W T W T W T W T
8H I W T W T W T W T W T W T W T W T W T W T W T
10 CR WT WT WT WT WT WT WT WT WT WT WT
11 HI WT WT WT WT WT WT WT L19F WT WT WT
12 CR V1417F WT WT WT WT WT WT WT WT WT WT
13 NR WT WT WT WT WT WT WT WT WT WT WT
14 PR WT WT WT WT WT WT WT WT WT WT WT
15 CR T1978P WT WT WT WT WT WT WT WT WT WT
16 NR WT WT WT WT S846N WT WT WT WT WT WT
17 NR N1068fsX13 WT WT WT WT WT WT WT WT WT WT
18 NR WT WT WT WT WT WT WT WT WT WT WT
19 NR P1962L WT WT WT WT WT WT WT WT WT WT
20 CR WT WT WT WT WT WT WT WT WT WT R882H
21 HI WT WT WT T726X WT WT WT WT WT WT WT
22 HI WT WT WT WT WT WT WT WT WT WT WT
Abbreviation: CR complete response; PR partial response; HI hematologic improvement; WT wild type
Table 2 Number and percentage of del[5q] detected
using metaphase cytogenetics, FISH and SNP-A alone or
in combination in myeloid malignancies (N = 122)
MC FISH SNP MC
+FISH
MC
+SNP
FISH
+SNP
MC+FISH
+SNP
Number 24 27 25 29 30 31 32
Percentage 20% 22% 21% 24% 25% 25% 26%
MC metaphase cytogenetics; FISH fluorescence in situ hybridization; SNP single
nucleotide polymorphism array-based karyotyping.
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Page 4 of 10Table 3 Summary of clinical characteristics of patients without del[5q] on MC who received lenalidomide (N = 42)
Diagnosis (No. of Patients)
MDS 31
RA 5
RARS 13
RCMD 1
RAEB-1 4
RAEB-2 7
MDS-U 1
MDS/MPN 7
CMML-1 2
CMML-2 2
MDS/MPN-U 3
PMF 2
sAML 2
Age (years old)
Median (Range) 70 (46-83)
Sex (No. of Patients)
M2 8
F1 4
IPSS (No. of Patients)
LOW 12
INT-1 11
INT-2 7
HIGH 1
not indicated 11
Duration of MDS (months)
Median (Range) 15 (0-118)
Previous Therapies
Yes 27
No 15
Transfusion dependence (No. of Patients)
Yes 30
No 12
Neutropenia (< 1.5 × 10
9/μ) (No. of Patients)
Yes 5
No 37
Thrombocytopenia (< 100 × 10
9) (No. of Patients)
Yes 12
No 30
Therapy (No. of Patients)
LEN (5-10 mg/day) alone 30
LEN high dose (50 mg/day) 1
LEN/AZA 11
Duration of LEN therapy (months)
Median (Range) 5 (0-76)
Response to therapy (No. of Patients)
CR 9
PR 3
HI 10
NR 16
NE 4
Abbreviation: MDS myelodysplastic syndromes; RA refractory anemia; RARS refractory anemia with ring sideroblasts; RCMD refractory cytopenia with multilineage
dysplasia; RAEB refractory anemia with excess blasts, MDS-U MDS unclassifiable; MDS/MPN MDS/myeloproliferative neoplasm; CMML chronic myelomonocytic
leukemia; MDS/MPN-U MDS/MPN unclassifiable; PMF primary myelofibrosis; sAML secondary acute myeloid leukemia; M male; F female; LEN lenalidomide; LEN/AZA
LEN/azacitidine; CR complete response; PR partial response; HI hematological improvement; NR no response; NE not evaluated.
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[HI], N = 9; no response [NR], n = 13; not evaluated
[NE], n = 4), and 11 patients received LEN/azacitidine
(AZA) combination therapy (CR, N = 6; PR, N = 1; HI,
N = 1; NR, N = 3). Only 1 patient had past history of
Hodgkin’s lymphoma and was suspected to have ther-
apy-related MDS/MPN.
By MC, 32 patients (76%) who received treatment
with LEN showed a normal karyotype, 1 patient (2.4%)
had no growth to their bone marrow sample, and 9
(21%) had an abnormal karyotype other than del[5q]
(Table 4). However, the frequency of an abnormal kar-
yotype was increased to 67% using FISH and SNP-A as
karyotyping tools in patients receiving LEN without
del[5q] by MC (Figure 2). Previously cryptic del[5q]
was detected by both SNP-A and FISH in an additional
1/18 patients with normal MC (Case 19 in Table 4).
Del[5q] was also revealed by FISH in 1 patient with
unsuccessful MC (Case 14 in Table 4), but, due to the
small size of the clone (8%), SNP-A was not able to
detect this lesion.
Impact of chromosomal abnormalities on response
In 27 patients who received LEN for more than 2
months, the overall response rate (ORR) was 52%,
including 3 CR, 2 PR and 9 HI. Case 19, who was diag-
nosed as sAML with del[5q] by FISH and SNP-A only,
was refractory to high-dose LEN. Case 14, a MDS/MPN
unclassifiable (MDS/MPN-U) patient in whom a del[5q]
clone was detected only by FISH due to the small size,
had a sustained PR with transfusion independence. The
ORR to LEN in patients with normal MC was 60%, vs.
17% for those with chromosomal aberrations by MC (p
= .08); the addition of FISH or SNP-A did not improve
the predictive value of normal cytogenetics (Table 5).
We also analyzed 11 patients without del[5q] by MC
who received combination therapy with AZA and LEN,
for whom the ORR was 73% (6 CR, 1 PR, 1 HI). By MC,
8/11 patients had a normal karyogram and a response
of 75%, compared to 3 patients with chromosomal
lesions, 1 of whom did not respond. Similar to the
results with LEN alone, inclusion of defects detected by
SNP-A or FISH did not allow for better separation of
responders based on normal cytogenetics by MC. The
most frequent cytogenetic abnormality among the
patients who received LEN was gain of chromosome 8
material (6/42), followed by the loss of chromosome 20
material (5/42). Patients with gain of chromosome 8 had
high ORR to LEN (5 out of 6, 83%) and ORR in patients
with chromosome 20 abnormalities was 3 out of 5. The
response of patients with all other chromosomal
abnormalities by MC, FISH or SNP-A was 44%. These
findings indicate that responses tend to be more often
observed in patients with gain of chromosome 8
material by either of all 3 karyotyping methods (p =
.11), although 5 out of those 6 patients received com-
bined LEN/AZA therapy.
Impact of mutational status on response
In 21 LEN-treated patients (11 patients with LEN only
and 10 patients with LEN/AZA), somatic mutations
were found in TET2 (N = 5), EZH2 (N = 1), ASXL1 (N
=4 ) ,K-RAS (N = 1), and DNMT3A (N = 2) in 11
patients. ASXL1 and DNMT3,o rTET2 and ASXL1
mutations were each found in one patient, and each of
these patients achieved CR with LEN/AZA or PR with
LEN only. ORR was 73% in patients with any of investi-
gated mutations and 70% in patients without a mutation
(p = .36). For patients treated with LEN only, 3 out of 8
(38%) responders had mutations, and 1 out of 3 (33%)
non-responders harbored mutations.
Discussion
Though the mechanism of action of lenalidomide has
not been definitively determined, it purportedly works
through inhibition of phosphatase activity in the com-
mon deleted region (CDR) of 5q that plays a key role in
cell cycle regulation, through a defect in ribosomal pro-
tein function, via direct cytotoxic mechanisms in
patients with the del (5q) cytogenetic abnormality, and
supposedly through effects on the bone marrow micro-
environment in patients who do not have this lesion, via
abrogation of the effects of pro-apoptotic, pro-inflam-
matory cytokines [1-3]. Until now, additional markers of
responsiveness to LEN beyond del[5q] have not been
identified.
New cytogenetic tools such as FISH and SNP-A are
likely to improve the diagnostic value of cytogenetic
diagnostics [8,9,29]. We first assumed that we would
detect previously unrecognized cases of del[5q] using
these techniques. In our cohort of patients given LEN,
del[5q] cases detected by FISH and/or SNP-A ranged
from 2 out of all 42 cases (4.8%) of patients without del
[5q] by MC, and 1 out of 32 cases (3.1%) with normal
MC. These frequencies are similar to those reported in
a previous study, in which 5.96% of cases without del
[5q] by MC and 2.7% of those with normal karyotype by
MC were found to be del[5q] by FISH [31]. These
results suggest that FISH and SNP-A may marginally
improve the detection rate of del[5q]. While the detec-
tion rate of cryptic del[5q] was only marginally
enhanced with FISH and SNP-A, new karyotyping tools
improved the detection rate of other chromosomal
abnormalities in our cohort from 21% to 67% compared
to MC. A previous study of 43 MDS patients suggested
that the cytogenetic pattern correlates with hematologic
response; 10 of 12 patients (83%) with del[5q] achieved
sustained red blood cell transfusion independence,
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Case Age
(y.o.)
Sex Diagnosis IPSS Therapy Response MC FISH SNP-
A
1 73 M RAEB-2 INT-2 LEN/AZA CR N N Gain 4q13.2
2 75 M RAEB-1 INT-1 LEN/AZA CR N trisomy
8
9% Gain 8q11.1q11.21
UPD 11q14.1q21
3 62 M MDS/MP
N-U
INT-1 LEN/AZA PR N N UPD 1pterp32.3
UPD 3p21.31p21.1
4 68 M RAEB-2 HIGH LEN/AZA NR complex karyotype, including trisomy 8, del
[7q], del[12], and del[20]
del[7q] 68% Gain 8
del[20q] 60% Loss 11p14.3p13
trisomy
8
41% Loss 12p12.3p11.21
Loss 12q21.1q21.31
Loss 16q22.3q24.3
Loss 1p22.2p22.1
Loss 20q11.2q13.33
Loss 21q11.2q21.1
Loss 2q31.3q32.1
Loss 6q23.3
Gain 7q11.21q11.22
Loss 7q22.1q36.2
5 68 M RAEB-2 INT-2 LEN/AZA CR 47,XY,+8[6] trisomy
8
9% Gain 14q11.1q11.2
UPD 19p13.11p12
Gain 8p23.3q24.3
6 73 M CMML-1 NE LEN PR N del[20q] 10% UPD 9pterp22.2
7 67 M PMF NE LEN PR N N Loss 11q23.3
8 66 M RCMD LOW LEN HI 46,XY,del(20)(q11q13)[2]/4 6,XY[18] del[20q] 17% Gain 8q11.1q11.23
9 69 M RAEB-1 INT-2 LEN/AZA CR N N NE
10 64 M MDS/MP
N-U
NE LEN CR N N N
11 79 F CMML-2 NE LEN/AZA HI 47,XX,+8[20] trisomy
8
42% Gain 8
12 62 F RAEB-2 INT-2 LEN/AZA CR N N N
13 62 F RARS INT-1 LEN NR 46,XX,add(15)(p11.1),add(2 2)(p11.2)[3]/47,
idem,+19[19].
del[7q] 11% Gain 19
del[7] 6% Gain 3q26.1
Gain 4p16.2
14 72 M MDS/
MPN-U
INT-2 LEN PR no growth del[5q] 8% Loss 20q11.1q13.12
del[20q] 35% Loss 2p21p24.1
Loss 8q11.23q12.1
Gain 9p12pter
15 63 M RAEB-2 NE LEN/AZA CR N N Gain 12q24.32
Gain 8q11.1
16 81 F RAEB-2 INT-2 LEN/AZA NR N N N
17 69 M CMML-2 - LEN/AZA NR N NE Loss 2p22.3
18 46 M PMF - LEN NR balanced translocation at chromosomes 2
and 22
NE UPD 14q31.3q32.33
Gain 9p24.3p11.1
19 70 F sAML - LEN (High
dose)
NR N del[5q] 33% Loss 5q31.2
20 65 F RARS LOW LEN CR N NE N
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and 12% of those with other karyotypic abnormalities
[1,32]. Consequently, we hypothesized that improved
detection of chromosomal abnormalities may better
predict poor response to LEN. However, when more
abnormalities were found using additional methods, no
correlation with response to LEN or LEN/AZA therapy
was detected.
Abnormal cytogenetics
Normal cytogenetics
Unsuccessful MC
MC only MC + FISH + SNP-A
33%
67% 76%
21%
2.4%
Figure 2 Frequency of cytogenetic abnormalities by MC only, or by MC, FISH, and SNP-A. Compared to MC only (left), addition of FISH
and SNP-A (right) improved the detection rate of chromosomal abnormalities dramatically from 21% to 67% in patients receiving LEN without
del(5q) by MC (N = 42).
Table 4 Patients characteristics who received LEN without del[5q] by MC (N = 42) (Continued)
21 70 M CMML-1 INT-1 LEN HI N N UPD 7q22.1qter
22 83 M RARS LOW LEN HI N N N
23 83 M RARS INT-1 LEN NR N NE N
24 71 M MDS-U INT-1 LEN NE N NE Loss 15q14
25 69 M RARS LOW LEN NR N NE N
26 76 M RA INT-1 LEN NR N NE Loss 3p22.3
27 68 M RA INT-1 LEN NR N NE Loss 21q21.2
Gain 3p14.1
Loss 11q14.3
28 59 M RARS LOW LEN NR N NE N
29 73 F RA LOW LEN NR N NE N
30 78 F RARS LOW LEN NE N NE UPD 3q21.3qter
31 78 M RAEB-1 INT-2 LEN NR 47,XY,+19 NE Gain 19
32 80 M RAEB-1 INT-1 LEN NE N NE Loss 17q11.2
UPD 8p11.2qter
33 79 F RARS INT-1 LEN HI N NE N
34 73 F RARS LOW LEN HI N NE Loss 18p11.32
35 78 F sAML - LEN NR 46,XX,t(3;3) NE Loss 3q26.1
36 80 M RAEB-2 INT-2 LEN NR N NE Loss 22q13.2
37 69 M RARS LOW LEN HI N NE N
38 59 F RA LOW LEN HI N NE N
39 62 F RARS LOW LEN NE N NE Gain 6p21.32
40 82 M RARS INT-1 LEN NR 46,XY,del(20)(q11.2) NE Loss 20q11.2q13.2
41 53 M RARS LOW LEN HI N NE N
42 56 F RA INT-1 LEN HI N NE Loss 9p21.2
Gain 1p21.1
Abbreviation: M male; F female; RAEB refractory anemia with excess blasts; MDS/MPN-U myelodysplastic syndromes/myeloproliferative neoplasm, unclassifiable;
CMML chronic myelomonocytic leukemia; PMF primary myelofibrosis; RCMD refractory cytopenias with multilineage dysplasia; RARS refractory anemia with ring
sideroblasts; sAML secondary acute myeloid leukemia; MDS-U, MDS unclassifiable; RA refractory anemia; LEN lenalidomide; AZA azacitidine; N normal; UPD
uniparental disomy; NE not evaluated.
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Page 8 of 10We also speculated that we could recognize other
chromosomal markers of response or refractoriness to
LEN besides del[5q] using FISH and SNP-A. For exam-
ple, trisomy 13 as the sole cytogenetic abnormality was
reported to be possible good prognostic factor to LEN
therapy [33], but was not detected in our LEN cohort.
Instead, we found gain of chromosome 8 material to be
predictive of response to LEN, although we acknowledge
that 5 out of those 6 patients received combined LEN/
AZA therapy [34,35].
In addition to cytogenetic abnormalities, we also stu-
died mutational status of a variety of genes as possible
markers of response. For example, ASXL1 mutations in
CMML [36] and DNMT3A in AML [27] were reported
to be poor prognostic factors. We identified 2 patients
with DNMT3A mutations in our cohort, both of them
achieved CR with LEN or LEN/AZA therapy.
This cohort used in this study has several limitations,
including a limited size and the inclusion of patients
with heterogenous disease entities. But, we have been
able to demonstrate that a normal karyotype and gain of
chromosome 8 material was predictive of response to
LEN, while additional testing by FISH or SNP-A is not
useful for better prediction of response in non-del[5q]
patients with myeloid malignancies.
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